HMGCR gene polymorphism is associated with residual cholesterol risk in premature triple-vessel disease patients treated with moderate-intensity statins
-
Published:2023-06-24
Issue:1
Volume:23
Page:
-
ISSN:1471-2261
-
Container-title:BMC Cardiovascular Disorders
-
language:en
-
Short-container-title:BMC Cardiovasc Disord
Author:
Li Jiawen,Tang Xiaofang,Xu Jingjing,Liu Ru,Jiang Lin,Xu Lianjun,Tian Jian,Feng Xinxing,Wu Yajie,Zhang Yin,Wang Dong,Sun Kai,Xu Bo,Zhao Wei,Hui Rutai,Gao Runlin,Song Lei,Yuan Jinqing,Zhao Xueyan
Abstract
Abstract
Background
To investigate the association of HMGCR and NPC1L1 gene polymorphisms with residual cholesterol risk (RCR) in patients with premature triple-vessel disease (PTVD).
Methods
Three SNPs within HMGCR including rs12916, rs2303151, and rs4629571, and four SNPs within NPC1L1 including rs11763759, rs4720470, rs2072183, and rs2073547 were genotyped. RCR was defined as achieved low-density lipoprotein cholesterol (LDL-C) concentrations after statins higher than 1.8 mmol/L (70 mg/dL).
Results
Finally, a total of 609 PTVD patients treated with moderate-intensity statins were included who were divided into two groups: non-RCR group (n = 88) and RCR group (n = 521) according to LDL-C concentrations. Multivariate logistic regression showed the homozygotes for the minor allele of rs12916 within HMGCR gene (CC) were associated with a 2.08 times higher risk of RCR in recessive model [odds ratio (OR): 2.08, 95% confidence interval (CI): 1.16–3.75]. In codominant model, the individuals homozygous for the minor allele of rs12916 (CC) were associated with a 2.26 times higher risk of RCR (OR: 2.26, 95% CI: 1.16–4.43) while the heterozygous individuals (CT) were not, compared with the individuals homozygous for the major allele of rs12916 (TT). There was no significant association between the SNPs within NPC1L1 gene and RCR in various models.
Conclusions
We first reported that the variant homozygous CC of rs12916 within HMGCR gene may incur a significantly higher risk of RCR in PTVD patients treated with statins, providing new insights into early individualized guidance of precise lipid-lowering treatment.
Funder
National Key Research and Development Program of China CAMS Innovation Fund for Medical Sciences Young and middle-aged talents in the XPCC Science and Technology Project
Publisher
Springer Science and Business Media LLC
Subject
Cardiology and Cardiovascular Medicine
Reference39 articles.
1. Report on Cardiovascular Health and Diseases in China. 2021: An Updated Summary. Biomed Environ Sci 2022, 35(7):573–603. 2. Mihaylova B, Emberson J, Blackwell L, Keech A, Simes J, Barnes EH, Voysey M, Gray A, Collins R, Baigent C. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet. 2012;380(9841):581–90. 3. Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, Braun LT, de Ferranti S, Faiella-Tommasino J, Forman DE, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139(25):e1082–143. 4. Giugliano RP, Cannon CP, Blazing MA, Nicolau JC, Corbalán R, Špinar J, Park JG, White JA, Bohula EA, Braunwald E. Benefit of adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in patients with Versus without Diabetes Mellitus: results from IMPROVE-IT (improved reduction of outcomes: Vytorin Efficacy International Trial). Circulation. 2018;137(15):1571–82. 5. Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, Kuder JF, Wang H, Liu T, Wasserman SM, et al. Evolocumab and Clinical Outcomes in patients with Cardiovascular Disease. N Engl J Med. 2017;376(18):1713–22.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|